Nuvation Bio
NUVB
127 hedge funds and large institutions have $267M invested in Nuvation Bio in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 18 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
5% more funds holding
Funds holding: 121 → 127 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.07% less ownership
Funds ownership: 65.26% → 64.19% (-1.1%)
16% less capital invested
Capital invested by funds: $318M → $267M (-$50.2M)
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$11.3M |
| 2 |
BlackRock
New York
|
+$1.44M |
| 3 |
Millennium Management
New York
|
+$763K |
| 4 |
HF
HRT Financial
New York
|
+$672K |
| 5 |
Two Sigma Advisers
New York
|
+$646K |
Top Sellers
NUVB Hedge Fund Activity: Q4 2022 in Review
127 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q4 2022, worth a combined $267M — down 16% from $318M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NUVB positions and 18 closed out — a net gain of 6 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Deerfield Management, adding an estimated $11.3M. The largest seller was Baupost Group, cutting an estimated $11.4M.
- 127 institutional investors held Nuvation Bio (NUVB) as of Q4 2022, up from 121 in Q3 2022.
- Funds reported $267M of Nuvation Bio stock for Q4 2022, down 16% quarter-over-quarter.
- 24 funds opened new Nuvation Bio positions in Q4 2022 and 18 closed out, a net change of +6 holders.
- The largest Nuvation Bio buyer in Q4 2022 was Deerfield Management, an estimated $11.3M added.
- The largest Nuvation Bio seller in Q4 2022 was Baupost Group, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2022.